RGEN Stock Summary and Trading Ideas (Repligen | NASDAQ:RGEN)

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Repligen trades on the NASDAQ stock market under the symbol RGEN.

As of May 10, 2024, RGEN stock price climbed to $166.81 with 292,997 million shares trading.

RGEN has a beta of 2.47, meaning it tends to be more sensitive to market movements. RGEN has a correlation of 0.40 to the broad based SPY ETF.

RGEN has a market cap of $9.30 billion. This is considered a Mid Cap stock.

Last quarter Repligen reported $151 million in Revenue and $.28 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.02.

In the last 3 years, RGEN stock traded as high as $327.32 and as low as $110.45.

The top ETF exchange traded funds that RGEN belongs to (by Net Assets): VTI, IJH, VB, VXF, VBK.

RGEN has underperformed the market in the last year with a price return of +7.7% while the SPY ETF gained +27.8%. RGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.6% and +0.1%, respectively, while the SPY returned +4.2% and +2.5%, respectively.

RGEN support price is $160.63 and resistance is $169.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGEN stock will trade within this expected range on the day.